Harvard Bioscience Stock
Harvard Bioscience, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- John D. Duke
- Employees
- 328
- Market cap
- $37 M
- IPO
- 07/12/2000
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump…
Harvard Bioscience stock: price history
1D
-2.6%
1W
-1.8%
1M
+1.5%
6M
+32.0%
YTD
+20.9%
1Y
+102.3%
2Y
-66.8%
5Y
-88.2%
10Y
-68.9%
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~55% stronger price swings than usual
Ask the agents about Harvard Bioscience
Analyst assessment of Harvard Bioscience
PRICE TARGET LOW
US$6.00
CONSENSUS
US$38.00
MEDIAN
US$38.00
PRICE TARGET HIGH
US$70.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 12/08/2026
Harvard Bioscience stock metrics
P/E
-3.48
P/B
4.94
EV/EBITDA
-42.52
RETURN ON EQUITY
-39.2%
NET MARGIN
-12.8%
DEBT/EQUITY
5.96
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.5%
FLOAT SHARES
3,665,971
AVG. DAILY VOLUME (30D)
16,438
Insider transactions (SEC)
Eade Katherine A.
Benson Seth Benjamin
Gagnon Robert E.
DENELSKY STEPHEN J
Snider William
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Harvard Bioscience stock
What does Harvard Bioscience do?
Harvard Bioscience, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is John D. Duke, the company employs around 328 people.
The IPO was on 07/12/2000; the stock trades on NASDAQ under the ticker HBIO.
What do analysts say about Harvard Bioscience stock?
5 analysts rate the stock, the consensus is Buy (as of 12/08/2026).
The average price target is US$38.00, ranging from US$6.00 to US$70.00, with a median of US$38.00.
This is an external assessment, not a statement by Market Jury.
When does Harvard Bioscience report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 55% stronger than usual.
Does Harvard Bioscience pay a dividend?
No, Harvard Bioscience currently does not pay a dividend.
Which stocks are comparable to Harvard Bioscience?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Harvard Bioscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Harvard Bioscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.